Background-Sarcoplasmic reticulum calcium ATPase 2a (SERCA2a) gene therapy improves mechanical function in heart failure and is under evaluation in a clinical trial. A critical question is whether SERCA2a gene therapy predisposes to increased sarcoplasmic reticulum calcium (SR Ca 2ϩ ) leak, cellular triggered activity, and ventricular arrhythmias in the failing heart. Methods and Results-We studied the influence of SERCA2a gene therapy on ventricular arrhythmogenesis in a rat chronic heart failure model. ECG telemetry studies revealed a significant antiarrhythmic effect of SERCA2a gene therapy with reduction of both spontaneous and catecholamine-induced arrhythmias in vivo. SERCA2a gene therapy also reduced susceptibility to reentry arrhythmias in ex vivo programmed electrical stimulation studies. Subcellular Ca 2ϩ homeostasis and spontaneous SR Ca 2ϩ leak characteristics were measured in failing cardiomyocytes transfected in vivo with a novel AAV9.SERCA2a vector. SR Ca 2ϩ leak was reduced after SERCA2a gene therapy, with reversal of the greater spark mass observed in the failing myocytes, despite normalization of SR Ca 2ϩ load. SERCA2a reduced ryanodine receptor phosphorylation, thereby resetting SR Ca 2ϩ leak threshold, leading to reduced triggered activity in vitro. Both indirect effects of reverse remodeling and direct SERCA2a effects appear to underlie the antiarrhythmic action. Conclusions-SERCA2a gene therapy stabilizes SR Ca 2ϩ load, reduces ryanodine receptor phosphorylation and decreases SR Ca 2ϩ leak, and reduces cellular triggered activity in vitro and spontaneous and catecholamine-induced ventricular arrhythmias in vivo in failing hearts. SERCA2a gene therapy did not therefore predispose to arrhythmias and may represent a novel antiarrhythmic strategy in heart failure. (Circ Arrhythm Electrophysiol. 2011;4:362-372.)
Clinical Perspective on p 372
One concern raised is whether SERCA2a gene transfer to the failing myocardium may predispose to increased arrhythmic potential, despite the improvements in inotropic and lusitropic function. However, the studies of SERCA2a expression and arrhythmogenesis that raise these concerns have been performed on a normal rather than a failing myocardial background. 6, 7 The sarcoplasmic reticulum (SR) of the failing ventricular myocardium is characterized by increased spontaneous diastolic calcium (Ca 2ϩ ) release, frequently measured as Ca 2ϩ sparks in isolated cardiomyocytes, reflecting an increased opening probability of the ryanodine receptors (RyR2). 8, 9 As luminal SR Ca 2ϩ levels contribute to RyR2 gating 10, 11 and provide the electrochemical driving force for SR Ca 2ϩ release, 12 elevating SR Ca 2ϩ by restoring SERCA2a function could hypothetically increase spontaneous Ca 2ϩ release and trigger arrhythmias. This would be a particular concern given the increased sympathetic drive seen in HF patients, as ␤ 1 -adrenoceptor activation increases both SR Ca 2ϩ loading by SERCA2a and may increase the risk of RyR2-mediated diastolic leak. 9 In the first clinical SERCA2a gene therapy trials, all patients have mandatory implantable defibrillators or left ventricular assist device support that will offer protection against malignant arrhythmias. However, if SERCA2a gene therapy is to be extended to the wider HF population, are these precautions against proarrhythmia required?
In the present study, we sought to address these specific concerns relating to SR Ca 2ϩ leak and arrhythmogenesis in the failing heart after SERCA2a gene transfer. We studied spontaneous and catecholamine-induced arrhythmia generation in vivo in a chronic HF model before and after heterogeneous SERCA2a gene transfer using ECG telemetry and ex vivo with provocation protocols aimed at producing reentry arrhythmias. A significant antiarrhythmic effect of SERCA2a gene transfer was detected and therefore we studied the potential mechanisms for the antiarrhythmic effect. Using a novel AAV9.SERCA2a vector, which yields more homogeneous (Ϸ90%) transfection efficiency 4 weeks after systemic venous delivery 13 and lacks the confounding effects of green fluorescent protein, we studied changes in cardiomyocyte SR Ca 2ϩ content and spontaneous SR Ca 2ϩ release events in freshly isolated failing cardiomyocytes after in vivo SERCA2a gene transfer.
Methods
Extended methods are included in the online-only Data Supplement.
Study Protocols
Two HF plus SERCA2a gene therapy cohorts were studied using a previously described rat model of postinfarction chronic HF ( Figure  1 ). 14 Sham -ligated (SHAM) or age-matched unoperated (AMC) animals served as nonfailing controls.
Cohort 1: In Vivo and Ex Vivo Arrhythmia Protocol
In vivo arrhythmia assessment was performed using implantable ECG telemetry with continuous 24-hour ECG recording for spontaneous ventricular arrhythmias, followed by an in vivo intraperitoneal injection of 0.5 mg/kg isoproterenol (ISO) for arrhythmia provocation. Recordings were performed in HF animals at baseline (PREGENE), and 6 days after receiving three 50 L intramyocardial injections of Ad.SERCA2a.GFP or Ad.GFP (POSTGENE) (GFP indicates green fluorescent protein). SHAM cases received 3 location-matched Ad.GFP injections. Twenty-four hours later, Langendorff-perfused hearts were studied for susceptibility to reentry arrhythmias using programmed electric stimulation. In a subgroup, left ventricular function was assessed 1 week after Ad.SERCA2a injection by pressure-volume (PV) analysis. 14
Cohort 2: HF؉AAV9.SERCA Study for Isolated Cardiomyocyte Studies
Sixteen HF rats received a 300 L tail-vein injection of AAV9.SERCA2a (2ϫ10 11 drp) at least 16 weeks after infarction. Four to 6 weeks later, hearts were harvested for either isolated cardiomyocyte studies (nϭ12) or Western blotting (nϭ4). A subgroup (nϭ6) underwent in vivo PV analysis before the rats were killed. HF rats without gene transfer and age-matched unoperated rats served as controls.
Isolated Cardiomyocyte Postcontraction Provocation Studies
The incidence of Ca 2ϩ -mediated delayed postcontractions was recorded in freshly isolated cardiomyocytes at baseline and after perfusion with 1 nmol/L ISO and 100 nmol/L ISO, with drug washout between doses.
Calcium Sparks, SR Calcium Load, and Leak
Spark studies were performed as previously described by our group, 14 with spark analysis based on the standard algorithm developed by Cheng et al. 15 Spark mass was calculated using the following equation: spark amplitudeϫ1.206ϫfull width at halfmaximal amplitude 3 , as previously reported. 16 Spark-mediated SR leak was the product of spark mass and frequency from individual myocytes. Total SR Ca 2ϩ leak was measured as the tetracainedependent SR Ca 2ϩ leak using the protocol described by Shannon et al, 17 with caffeine-sensitive SR Ca 2ϩ load measured in series allowing SR leak/load calculation for individual myocytes.
Ryanodine Receptor and Phospholamban Phosphorylation
Phosphorylation of RyR2 and phospholamban (PLB) at both protein kinase A (PKA) (RyR2809, PLB-Ser16) and calmodulin-dependent protein kinase II (CaMKII) (RyR2815, PLB-Thr17) target sites were measured by Western blotting.
Statistical Analysis
Results were compared using 1-way ANOVA with Tukey posttest comparison (quantitative arrhythmia and HF variables), Kruskal-Wallis test with Dunn posttest comparison (Ca 2ϩ spark parameters), paired Student t test (in vivo PREGENE and POSTGENE arrhythmias) and Fisher exact test (arrhythmia incidence). A probability value Ͻ0.05 determined statistical significance.
Results

SERCA2a Protein Levels After SERCA2a Gene Therapy
Focal GFP fluorescence in injected regions was demonstrated in all hearts receiving Ad.SERCA2a.GFP or Ad.GFP gene transfer in cohort 1, 7 days after intramyocardial gene injection (Figure 2A ). Ad.SERCA2a gene transfer signifi-cantly increased SERCA2a protein levels in the injected and remote uninjected regions compared with both fluorescent and nonfluorescent regions from HFϩGFP hearts (Pϭ0.01) ( Figure 2B and online-only Data Supplement Figure S1 ). Intravenous AAV9.SERCA2a gene transfer also successfully increased myocardial SERCA2a protein levels in failing rats in cohort 2 at 4 to 6 weeks after injection ( Figure 2C ).
In Vivo Left Ventricular Function (Cohorts 1 and 2)
Parameters of systolic and diastolic function and energetic efficiency, as measured by PV analysis, were significantly improved in HF rats after treatment with either Ad.SERCA2a,GFP, or AAV9.SERCA2a gene transfer compared with untreated HF controls, confirming previous observations that SERCA2a gene transfer acts as a positive inotrope and lusitrope in the failing heart ( Figure 2D through 2G). [2] [3] [4] Arrhythmia Studies: Cohort 1
In Vivo Arrhythmias
Spontaneous Ventricular Arrhythmias
This HF model is characterized by a high frequency of spontaneous ventricular arrhythmias (mean, 4269 ventricular arrhythmias per heart per day; nϭ16), with the majority being isolated ventricular ectopic (VE) beats (mean, 4025 VEs per heart per day; 94% of total ventricular arrhythmias) ( Figure  3A and 3B). Heterogeneous Ad.SERCA2a injection significantly reduced both the total number of spontaneous ventricular arrhythmias ( Figure 3A ) and the number of complex ventricular arrhythmias ( Figure 3B ), compared with HFϩGFP and the HF (PREGENE) phenotype. There was no difference in ventricular arrhythmia incidence in PREGENE HF cohorts between rats receiving Ad.SERCA2a and those receiving control Ad.GFP injections. Daily arrhythmia analysis after gene injection in a subgroup of cases showed a reduction in the arrhythmia burden with the predicted onset of SERCA2a transgene expression and no evidence for an early proarrhythmic effect on spontaneous ventricular arrhythmogenesis (online-only Data Supplement Figure S2 ). Spontaneous malignant ventricular arrhythmias (sustained ventricular tachycardia [VT] Ͼ30 seconds and reversible or fatal ventricular fibrillation [VF]) were rare, recorded in 2 of 16 HF rats (PREGENE), 2 of 8 HFϩGFP rats, 1 of 8 HFϩ SERCA2a rats, and absent in SHAM myocardial infarction (MI) cases. Analogous to in vitro studies of action potential duration with SERCA2a overexpression, 18 heterogeneous SERCA2a transduction significantly shortened the abnormally prolonged QT90 (ms) in this HF model in vivo: SHAM MIϩGFP, 60Ϯ2; HFϩGFP, 89Ϯ2; and HFϩSERCA, 77Ϯ2 (Pϭ0.005 versus HFϩGFP).
Isoproterenol-Induced Ventricular Arrhythmias
The in vivo ISO injection protocol (0.5 mg/kg), which produced matched heart rate responses in the 3 study groups (online-only Data Supplement Figure S3 ), induced a high incidence of malignant arrhythmias in the HF model. Fatal VF was triggered in 4 of 20 HF cases, with reversible VF observed in a further two HF (PREGENE) cases. ISOinduced VT was present in 11 of 16 surviving cases. Heterogeneous SERCA2a transfection significantly reduced the total number of ISO-induced ventricular arrhythmias during the 60-minute period after ISO injection ( Figure 3C ). Interestingly, SERCA2a transfection completely abolished ISOinduced VT and VF in the failing hearts, whereas ISOinduced VT was present in 15 of 20 (75%) of HF (PREGENE) and 5 of 8 (63%) of HFϩGFP animals but absent in SHAM MIϩGFP cases ( Figure 3D ).
Ex Vivo PES-Induced Ventricular Arrhythmias
SERCA2a transfection of the failing heart had an antiarrhythmic effect, significantly reducing both the incidence of PES-induced VT (37Ϯ16% versus 86Ϯ14% Pϭ0.04) and shortening the S2 interval (ms) at which VT was triggered (62Ϯ3 versus 73Ϯ3 Pϭ0.04) compared with HFϩGFP cases.
Arrhythmia Studies: Cohort 2
Isolated Cardiomyocyte Studies
Cardiomyocytes isolated from infarcted hearts displayed a typical failing phenotype, with slower Ca 2ϩ transient decay times ( Figure 4A ), reduced SR Ca 2ϩ content ( Figure 4B ) and increased spark frequency ( Figure 5 ). As noted above, AAV9.SERCA2a gene transfer increased myocardial SERCA2a protein levels in failing rats ( Figure 2C ), leading to restoration of SR Ca 2ϩ content and transient decay times toward normal levels ( Figure 4A and 4B).
Ca 2؉ Sparks
Ca 2ϩ spark frequency, and the ratio of Ca 2ϩ sparks:SR load, was higher in the failing myocytes but did not increase further after SERCA2a gene therapy ( Figure 5B and 5E ), suggesting that the increased SR Ca 2ϩ content after SERCA2a treatment did not promote additional increases in RyR2 opening frequency in failing cardiomyocytes with a baseline "leaky" SR. Ca 2ϩ spark mass, a parameter reflecting the amount of calcium released with each spark, was significantly increased in failing myocytes and reduced to normal levels in failing myocytes after SERCA2a gene transfer ( Figure 5C ). The total spark-mediated SR Ca 2ϩ leak, the product of spark mass and frequency, was also reduced by SERCA2a gene transfer ( Figure 5D ). Interestingly, after SERCA2a gene therapy, the degree of spark-mediated SR Ca 2ϩ leak per unit SR Ca 2ϩ load was significantly reduced ( Figure 5F ).
Total SR Ca 2؉ Leak
It has been recently reported that SR Ca 2ϩ leak may also result from spark-independent mechanisms. 19 To account for this, "total" SR Ca 2ϩ leak was measured using tetracaine perfusion to inhibit RyR2 opening in cardiomyocytes isolated from a separate cohort of study hearts ( Figure 6 ). Tetracainedependent SR Ca 2ϩ leak was increased in cardiomyocytes from the HF model and was lowered to normal levels in myocytes from HFϩSERCA2a hearts ( Figure 6Bi ). The SR Ca 2ϩ content in this group of failing cardiomyocytes was reduced and elevated back toward normal levels after SERCA2a gene transfer (Figure 6Bii ; see reproducible change matched in Figure 4B ). Similar to the spark-mediated leak, total SR Ca 2ϩ leak, when corrected for matched SR Ca 2ϩ load, showed that rescue by SERCA2a gene therapy restored a normal SR Ca 2ϩ load/leak relationship ( Figure  6Biii ). These results confirmed that SR Ca 2ϩ leak threshold is lowered in HF (consistent with previously reported studies), and this threshold is raised back toward normal levels after rescue by SERCA2a gene therapy.
RyR2 Phosphorylation
Potential RyR2-dependent mechanisms for resetting of the SR Ca 2ϩ leak threshold were explored by measurement of RyR2 phosphorylation status. Phosphorylation at serine 2815, the CaMKII site, after correction for total RyR2 levels, was increased in the HF model, and reduced to normal levels after SERCA2a gene therapy (Figure 7 ). Phosphorylation of PLB at the CaMKII site Thr17 was also increased in failing myocytes. SERCA2a demonstrated a trend to reduced phosphorylation at PLB-Thr17, particularly in the PLB monomer fraction (Pϭ0.06 versus HF). Both RyR and PLB phosphorylation by PKA were increased in the HF model but unchanged after SERCA2a gene therapy (Figure 7 ).
Triggered Activity in Isolated Cardiomyocytes
Consistent with the observation of reduced spontaneous SR Ca 2ϩ leak, and despite both increased SR content and unaltered spark frequency, cardiomyocytes from HFϩSERCA hearts were more stable in vitro, with significantly fewer basal and ISOinduced Ca 2ϩ -mediated delayed aftercontractions compared with HF controls (Figure 8 ).
Discussion
A number of preclinical studies have shown that restoration of SERCA2a protein levels and activity by gene therapy improves cardiac function in failing ventricular myocardium. [1] [2] [3] [4] SERCA2a gene therapy represents the first therapeutic strategy specifically targeting abnormal Ca 2ϩ cycling in HF to be tested in a clinical trial. 5 However, concerns regarding the potential for SERCA2a gene transfer to increase ventric-ular arrhythmia susceptibility via disruption of the SR loadleak equilibrium in favor of increased leak have been raised. 6 Failing ventricular cardiomyocytes are characterized by increased spontaneous SR Ca 2ϩ release events (sparks) despite reduced SR Ca 2ϩ stores and, intuitively, reloading a leaky SR by restoring SERCA2a activity could be proarrhythmic, given the mechanistic links between SR Ca 2ϩ leak, triggered activity, and ventricular arrhythmogenesis. 20 Furthermore, heterogeneous restoration of SERCA2a levels using the current vectors and delivery techniques may increase the dispersion of depolarization, a biophysical property that supports continuous wave front propagation through the failing ventricular myocardium. 21 This study was designed to investigate the influence of SERCA2a gene transfer on arrhythmia generation and specifically the potential to influence Ca 2ϩ -induced arrhythmias in the failing heart. The main findings of this study were (1) SERCA2a gene transfer significantly reduced spontaneous and ISO-induced ventricular arrhythmic events in vivo, completely abolishing ISO-induced VT and VF ( Figure 3 ); (2) SERCA2a gene transfer significantly reduced the degree of QT prolongation and the incidence of PES-induced VT and shortened the S2 cycle length at which VT was initiated compared with failing hearts; (3) SERCA2a gene transfer normalized Ca 2ϩ transient decay kinetics and reduced the incidence of ISO-induced Ca 2ϩ -mediated delayed aftercontractions in failing cardiomyocytes (Figures 4 and 8) ; (4) SERCA2a gene therapy did not lower (or raise) spontaneous Ca 2ϩ spark frequency but significantly reduced spark mass that had been raised in the HF model. Both spark-mediated and total SR Ca 2ϩ leak were reduced after SERCA2a gene therapy despite the normalized SR Ca 2ϩ load. (Figure 5 to 6); (5) SERCA2a reduced RyR2 phosphorylation at CaMKII sites to normal levels, suggesting that molecular remodeling underlies resetting of the SR Ca 2ϩ leak threshold (Figure 7) .
What underpins this significant antiarrhythmic effect of SERCA2a gene transfer in the failing heart? Several potential direct and indirect mechanisms may contribute, and it is important to note that these are not mutually exclusive.
Reduced Arrhythmogenic SR Ca 2؉ Leak
Increased Ca 2؉ Buffering by SERCA2a
Results from the isolated cell studies support a direct antiarrhythmic effect on intracellular Ca 2ϩ homeostasis. SERCA2a gene therapy reduced SR Ca 2ϩ leak compared with failing cardiomyocytes: Because the leak is recognized to be proarrhythmic, 8, 20 a reduction will be beneficial. Restored SERCA2a levels may directly influence spark morphology and arrhythmic potential by limiting the spatial spread of Ca 2ϩ and preventing local Ca 2ϩ elevation to the threshold levels that initiate and propagate internal Ca 2ϩ -induced Ca 2ϩrelease, spontaneous Ca 2ϩ waves and delayed afterdepolarizations. Inhibiting SERCA2a activity pharmacologically has previously been reported to prolong Ca 2ϩ spark decay and increase the space constant of spread for the released Ca 2ϩ ions. 22 Reduced delayed afterdepolarization frequency in failing cells after SERCA2a gene transfer was evident both spontaneously and particularly in the presence of ␤-adrenergic receptor activation. Conceivably, this may reflect the increased Ca 2ϩ sink resulting directly from increased SERCA2a activity and indirectly via the restored capacity of other cytoplasmic Ca 2ϩ buffers, which may be saturated in the failing heart. Modeling of intracellular Ca 2ϩ release and Ca 2ϩ waves in ventricular cardiomyocytes demonstrated the importance of resting cytoplasmic Ca 2ϩ levels and buffering capacity to influence the probability of wave propagation. 23 In summary, the buffering effect of restored SERCA2a levels and activity in the failing cardiomyocyte after gene transfer acts to stabilize the cell, reducing the magnitude of the SR Ca 2ϩ leak, and preventing the conversion of the residual Ca 2ϩ leak into arrhythmogenic delayed afterdepolarizations.
Stabilization of RyR2 Gating
Stabilization of RyR2 gating also represents an antiarrhythmic mechanism. The SR leak phenotype in this HF model is reminiscent of that observed under other circumstances in which RyR2 opening probability is increased, such as after application of FK506 to normal myocytes 24 or in mice overexpressing CaMKII. 25 RyR2 mutations leading to increased Ca 2ϩ sensitivity and opening probability also increase spark frequency despite reduced SR Ca 2ϩ load. 26 Recently it has been reported that aldosterone, which is increased in the serum and myocardium in chronic HF patients, stimulates increased spark frequency, reflecting increased RyR2 opening probability and SR Ca 2ϩ leak. 27 Reduced Ca 2ϩ leak after SERCA2a gene transfer to failing cardiomyocytes may reflect stabilized RyR2 gating. Phosphorylation of RyR2 at both PKA and CaMKII sites, both elevated in this HF model, is known to increase RyR2 opening probability. 8, 9 Phosphorylation at serine 2815, the putative CaMKII site, was reduced to normal levels in the SERCA2a treated failing hearts (Figure 7) . A recent report highlights the importance of the S2815 CaMKII RyR2 phosphorylation site in the generation of arrhythmias in HF. 28 Transgenic mice in which S2814 (the murine residue analogous to S2815 in the rat) is constitutively activated via mutagenesis (S2814D) developed HF, increased SR Ca 2ϩ leak, and catecholamine-induced ventricular arrhythmias. In contrast, genetic ablation of this RyR2 phosphorylation site (S2814A) protected against catecholamine-induced arrhythmias in an aortic constriction model. 28 Analogous phospholamban phosphorylation is also consistent with reduced functional CaMKII activity in the failing hearts after SERCA2a gene therapy. CaMKII activation in hypertrophy and HF may result from either higher basal Ca 2ϩ levels, with increased formation of calmodulin-Ca 2ϩ complexes or increased levels of oxidative stress via Ca 2ϩindependent activation. 29, 30 SERCA2a gene transfer to failing cardiomyocytes lowers basal Ca 2ϩ levels and improves myocardial energetics, a possible surrogate for lower levels of oxidative stress (Figure 2E) , with both changes lowering CaMKII activation. RyR2 stabilization may be further enhanced by lower basal cytoplasmic Ca 2ϩ secondary to enhanced SERCA2a function as well as better local mitochondrial function resulting in improved local redox status with reduced RyR2 oxidation by reactive oxygen species. 31 One proposed mechanism for increased SR Ca 2ϩ leak in failing cells is a lowering of the luminal Ca 2ϩ threshold to trigger spontaneous opening, a process termed store overloadinduced Ca 2ϩ release (SOICR). 11, 32 When evaluated in terms of spark frequency, no change in spark frequency:SR load ratio after SERCA2a gene transfer was observed ( Figure 5E ), suggesting the restored SR Ca 2ϩ levels via this intervention do not alter RyR2 channel opening probability. However, placing both the reduced spark-mediated and total SR leak in the context of the normalized SR Ca 2ϩ load, it appears likely that RyR2 gating by luminal Ca 2ϩ may also have been altered to a more stable configuration, increasing the threshold for SOICR toward normal levels ( Figure 5F and 6Biii) . 32 This is supported by previous studies demonstrating that as SR leak increased the SR Ca 2ϩ load was reduced. 17 Our results suggest that in the chronically failing heart, there is a lower SOICR threshold with increased RyR2 phosphorylation and opening, greater leak, and hence lower SR Ca 2ϩ load. These changes are reversed after rescue by SERCA2a gene therapy, with lower levels of RyR2-2815 phosphorylation and reduced SR Ca 2ϩ leak, and simultaneously the capacity to achieve the increased SR Ca 2ϩ load observed in this and previous studies after SERCA2a gene transfer. 1
Indirect Antiarrhythmic Effects From Reverse Remodeling of the Failing Ventricle
Recovery of mechanical left ventricular function is reported in various animal models after SERCA2a gene therapy including this study. [2] [3] [4] By acting as a "molecular left ventricular assist device," the improved function of SERCA2a-treated hearts may translate to a reduction in arrhythmia generation via a number of potential indirect mechanisms. These include reduced wall tension and the detrimental effects of mechanical-electric feedback, 33 reduction of adverse gene expression profiles, 34 improved mitochondrial function, and cellular energetics. 35, 36 The significant improvement of diastolic function, as well as some measures of systolic function, would argue for a degree of functional recovery. The increased SERCA2a levels in the remote myocardium would be consistent with the hypothesis that reduction of arrhythmias is part of a global improvement, albeit produced by the focal delivery (cohort 1).
Several of lines of evidence exist from this study to suggest it is not purely the indirect benefits of reverse remodeling. First, in the model used (chronic post infarction HF), the persistent presence of a large infarct (39% to 44% of the left ventricle, Table S1 ) limits potential for full recovery of systolic function in either treated cohort. Second, we found no evidence of an acute proarrhythmic effect early in the SERCA2a-treated hearts when assessing spontaneous arrhythmias during the first 6 days after Ad.SERCA2a injection (online-only Data Supplement Figure S2 ). Indeed, the in vivo antiarrhythmic effect appeared during the first 48 hours after transgene delivery in the Ad.SERCA2a-treated cohort, at a time when significant structural reverse remodeling is unlikely to have occurred.
SERCA2a gene transfer initiates reverse remodeling in an energetically favorable manner (Figure 2E ), 2 and this may further accelerate the progression from an electrically unstable substrate to one with higher thresholds for arrhythmia inducibility and propagation. Even if an acute proarrhythmic effect were present (and we have shown evidence against this), then conceivably it could become balanced by the benefits of reverse remodeling of the failing myocardium.
It is also plausible that the slower kinetics for restoration of SERCA2a activity using the viral gene therapy approach may allow molecular reverse remodeling of SR-cytoplasmic Ca 2ϩ cycling and SR leak to be generated in a safer manner, compared with an acute activation of SERCA2a activity in the failing heart to immediate high levels using a pharmacological approach. However, again we have no evidence to support this concern, and no purely selective SERCA2a activators are currently available to test this hypothesis.
Reduced Susceptibility to Reentry Arrhythmias
Several lines of evidence suggest that repolarization was normalized and vulnerability to reentry arrhythmias were reduced in the failing rat ventricle after SERCA2a gene transfer, which may contribute to the antiarrhythmic effect. We have previously shown that SERCA2a expression shortens action potential duration in isolated cardiomyocytes. 18 In these studies, SERCA2a gene transfer reduced the QT interval, which was prolonged in this HF model. Restoring SERCA2a protein levels and activity in the failing heart resulted in reduced susceptibility to PES-induced reentry arrhythmias, and a narrowing of the time window of vulnerability to premature electric extrastimuli, demonstrated by both shortening of the S2 interval for VT inducibility and reduction of QT prolongation. Improving cardiomyocyte Ca 2ϩ cycling by SERCA2a gene therapy may therefore stabilize electric heterogeneities in the failing myocardium, an influence also observed after overexpression in the normal heart. 37
Failing Myocardial Substrate Is Critical for Beneficial Effects of SERCA2a Gene Therapy
It is interesting to contrast the findings of this study with those from SERCA2a overexpression studies in normal myocytes, which in some settings have demonstrated the potential for adverse effects with respect to excessive buffering 38 or proarrhythmia. 6 The context is critical. In these studies, supraphysiological SERCA2a levels were introduced on a background of normal myocyte physiology, and excessive SR-cytoplasmic Ca 2ϩ cycling in normal myocytes has detrimental effects, as observed in other models. 39, 40 In contrast, this paper highlights the beneficial effects of rescuing the failing myocyte, in which basal SERCA2a levels are low and contribute to both the mechanical dysfunction and arrhythmic substrate. The results of this study highlight that in this context (HF), restoring SERCA2a to normal levels via gene transfer stabilizes the SR Ca 2ϩ physiology and has a potent antiarrhythmic effect.
A limitation of this study is that rodent myocardial Ca 2ϩ physiology differs from human and is more SERCA2adependent. However, the majority of the findings concerning SR Ca 2ϩ load leak, which gave rise to the potential concerns regarding SERCA2a gene therapy in the "leaky" failing heart addressed in this report, are derived from studies in rodent hearts or isolated rat cardiomyocytes. The lack of increased leak or proarrhythmic effect in this sensitive model that shows high susceptibility to Ca 2ϩ -dependent arrhythmias is encouraging and reassuring, and accepting that only results from randomized controlled, double-blinded trials will answer the question regarding arrhythmogenesis in the human heart. To date, the 12-month follow-up of 39 patients with chronic HF receiving AAV1.SERCA2a gene therapy has been presented, and no proarrhythmic concerns have been reported (American Heart Association Scientific Sessions, 2010). 41 This would support our findings that SERCA2a gene therapy can impart the benefits of a positive inotrope and induce reverse remodeling while avoiding a proarrhythmic effect.
Conclusions
In summary, our study demonstrates significant antiarrhythmic effects of SERCA2a gene transfer in the rat after MI model of HF. Isolated ventricular myocytes from the un-treated failing hearts demonstrated increased spontaneous SR Ca 2ϩ leak and ISO-induced triggered activity in vitro, and animals with HF had increased spontaneous and catecholamine-induced arrhythmias in vivo. After SERCA2a gene transfer, SR Ca 2ϩ levels were restored, RyR phosphorylation at serine 2815 was normalized, spontaneous Ca 2ϩ sparks were smaller and decayed faster, and total SR leak was reduced, allowing the beneficial positive inotropic and lusitropic effects of SERCA2a gene therapy to occur without an associated proarrhythmic tendency. This suggests that SERCA2a gene therapy represents a novel therapeutic strategy with positive inotropic, lusitropic and antiarrhythmic benefits, as opposed to the proarrhythmic effects observed with other positive inotropes (eg, ␤-adrenergic receptor agonists and phosphodiesterase inhibitors). These antiarrhythmic effects of SERCA2a gene therapy appear to be the combination of both the indirect benefits of electric reverse remodeling in the recovering ventricle and direct effect of restored SERCA2a protein levels on intracellular calcium homeostasis, allowing the positive inotropic benefits to be obtained without a proarrhythmic cost. In contrast to the previous a priori concern, SERCA2a gene transfer does not predispose to arrhythmias and may even represent a novel antiarrhythmic strategy in HF.
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